Real-World Safety and Effectiveness of an Initial 0.1 mg Dose of Desmopressin in Older Men With Nocturnal Polyuria.

purposeWe investigated the safety and effectiveness of oral desmopressin tablet (starting dose 0.1 mg) in older Taiwanese men with nocturnal polyuria and nocturia and compared results in those aged ≥ 80 years vs < 80 years. MATERIALS AND

methodsTwo hundred thirty-four Taiwanese men aged 60 years or older with nocturia (≥2 voids/night) and a nocturnal polyuria index of ≥ 33 were included. Patients received desmopressin 0.1 mg for up to 3 months. Effectiveness was evaluated at Month 1, and safety was assessed at Months 1, 2, and 3.

resultsTwo hundred eight patients (88.9%) aged 60 to 95 years provided follow-up data. Of the participants 70.1% completed the 3-month treatment period. Desmopressin was associated with significantly reduced median nocturnal voids/night (<80 years: -2.0; ≥80 years: -3.0) and urine volume (<80 years: -705 mL; ≥80 years: -660 mL) and increased hours of undisturbed sleep (<80 years: 1.0 hours; ≥80 years: 2.0 hours; all

conclusionsThis study provides real-world evidence of effectiveness and safety of oral desmopressin in an older Asian male population, including a subgroup aged older than 80 years. A starting dose of 0.1 mg oral desmopressin, coupled with careful serum sodium monitoring and dose adjustment if required, was associated with significant improvement in all nocturia parameters and a high rate of continuation.